Please Wait
Applying Filters...
menu
    • menu
    Alchem offers Phytochemical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    PTG-300

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Protagonist doses first patient in Phase II study of PTG-300
    Protagonist doses first patient in Phase II study of PTG-300

    01 Nov 2019

    // CLINICALTRIALSARINA

    https://www.clinicaltrialsarena.com/news/protagonist-patient-study-ptg-300/

    CLINICALTRIALSARINA
    01 Nov 2019
    Share Share
    Protagonist Therapeutics Receives $1.45 Million SBIR Funding for PTG-300
    Protagonist Therapeutics Receives $1.45 Million SBIR Funding for PTG-300

    06 Sep 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/protagonist-therapeutics-receives-1-45-million-sbir-funding-for-the-development-of-ptg-300--300707776.html

    PR NEWSWIRE
    06 Sep 2018
    Share Share
    Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100
    Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100

    06 Jan 2016

    // PR NEWSWIRE

    http://www.prnewswire.com/news-releases/protagonist-therapeutics-initiates-phase-1-study-with-oral-peptide-ptg-100-300201405.html

    PR NEWSWIRE
    06 Jan 2016
    Share Share